Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument
April 27 2023 - 8:00AM
Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial
Biology Company®, today announced it has shipped it’s 1,000th
instrument, a significant milestone for the company and the largest
installed base in the spatial biology industry. Akoya platforms
have gained widespread adoption in discovery and translational
research laboratories around the world, setting the stage for
clinical use. Akoya’s industry leading instrument portfolio
includes the PhenoCycler®, PhenoImager® Fusion and the PhenoImager
HT.
“The shipment of our 1,000th instrument is a testament to our
unique ability to deliver end-to-end spatial solutions that enable
the identification and validation of spatial biomarkers with the
potential for use in the clinical setting to improve patient
outcomes,” said Brian McKelligon, CEO of Akoya Biosciences. “It is
gratifying to have reached this important milestone and I extend my
deepest appreciation to the entire Akoya team for their dedication
to the success of our organization and customers. We remain
committed to further expanding our ecosystem of technologies,
reagents, and software, ensuring that our customers have access to
the most advanced and comprehensive spatial biology solutions for a
broad range of applications.”
Placement of the 1,000th Akoya system reflects the quality,
power, and reliability of the company’s portfolio to address some
of the most complex biological questions.
“We are pleased that Akoya has chosen iHisto as the recipient of
the 1,000th instrument placement,” said Kelven Wong, CEO of iHisto,
a Salem, MA based histopathology lab support firm that provides
tissue processing and molecular pathology services with a focus on
routine histology, histological staining, target marker staining,
and whole-slide imaging. “iHisto seeks to promote affordable
histology services with a one-stop shop providing high-quality
results in an industry-leading turnaround time. We support routine
as well as cutting-edge histology services using leading
technologies such as Akoya’s PhenoCycler-Fusion, which enables
rapid, robust, and comprehensive tissue analysis through high-plex
spatial imaging.”
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:Priyam ShahSr. Director,
Investor RelationsAkoya Biosciences, Inc.investors@akoyabio.com
Media Contact:Christine Quern(617)
650-8497media@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Apr 2024 to May 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From May 2023 to May 2024